The Potentials of Glycomics in Biomarker Discovery by unknown
The Potentials of Glycomics in Biomarker Discovery
Richard K. T. Kam & Terence C. W. Poon
Published online: 4 September 2008
# Humana Press 2008
Abstract
Introduction Glycans have unique characteristics that are
significantly different from nucleic acids and proteins in terms
of biosynthesis, structures, and functions. Moreover, their
isomeric nature and the complex linkages between residues
have made glycan analysis a challenging task. Disease
development and progression are usually associated with
alternations in glycosylation on tissue proteins and/or blood
proteins. Glycans released from tissue/blood proteins hence
provide a valuable source of biomarkers. In this postgenome
era, glycomics is an emerging research field. Glycome refers
to a repertoire of glycans in a tissue/cell type, while glycomics
is the study of glycome. In the past few years, attempts have
been made to develop novel methodologies for quantitative
glycomic profiling and to identify potential glycobiomarkers.
It can be foreseen that glycomics holds the promise for
biomarker discovery. This review provides an overview of the
unique features of glycans and the historical applications of
such features to biomarker discovery.
Future Prospective The concept of glycomics and its recent
advancement and future prospective in biomarker research
are reviewed. Above all, there is no doubt that glycomics is
gaining momentum in biomarker research.
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Glycosylation is one of the most common posttranslational
modifications in eukaryotes, and a majority of cellular
proteins are glycosylated through eitherN- or O-glycosylation
or through glycophosphatidylinositol anchor pathway that
connects the protein with two fatty acid chains. Other
important glycoconjugates include glycosphingolipids,
lipopolysaccharides, and peptidoglycans. The attachment of
polysaccharides or glycans to biomolecules depends on the
physiological status of the cells [1] and the protein sequence
[2]. Glycosylation changes have been identified in various
diseases, ranging from systemic genetic diseases, like
congenital disorders of glycosylation (CDG) syndrome [3],
to localized malignancy, like ovarian cancers [4]. There has
been a long history in applying glycobiomarkers for disease
diagnosis and prognosis. Because of their diverse structures
and the information they carry, glycans provide a valuable
source of biomarkers. In this “Omics” era, the concept of
glycomics has evolved. In the past, research was restricted to
glycosylation analysis of individual glycoproteins, and large
scale glycome screening at tissue level was not possible
because of technical difficulties. With the recent advances in
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analytical technologies, glycomics and glycoproteomics is
gaining momentum in biomarker researches.
While genomics or proteomics have been relatively well
established and commonly applied to biomarker discovery
[5, 6], biomarker research is relatively unexplored through
glycomics perspective. This review will give an introduc-
tion of the characteristic of glycosylation and the historical
applications of glycobiology to biomarker research. The
concept of glycomics, its differences from glycoproteomics,
its recent advancement and future prospective in biomarker
research, and the technologies for quantitative profiling of
tissue glycome are then reviewed. Given the board
spectrum of glycomic studies in various diseases, it would
be impossible to provide an in-depth review for every
aspect in this review article. The focus of this article will be
mainly on the applications of N-linked and O-linked
glycans in biomarker discovery.
Overview of Biochemical and Functional
Characteristics of Glycan
Compared with DNA molecules and polypeptides, glycans
attached to glycoconjugates have three fundamental differ-
ences, which are (1) non-template-based synthesis, (2)
branching primary structures, and (3) variable linkages
between the basic units, i.e., monosaccharides. In humans,
the major glycan basic units include mannose (Man),
galactose (Gal), N-acetylgalactosamine (GalNAc), glucose
(Glc), N-acetylglucosamine (GlcNAc), sialic acid (or called
N-acetylneuraminic acid, Neu5Ac), and fucose (Fuc). In
contrast to the production of DNA molecules or polypep-
tides, which requires the presence of complementary DNA
strands or mRNAs, there is no template or blue-print
molecule for the production of oligosaccharides to be based
upon. The synthesis of a glycan depends on the activity of a
set of glycosidases and glycosyltransferases in rough
endoplasmic reticulum and Golgi apparatus and the target
molecule. To date, it is still impossible to predict
the structure(s) of the glycosylation side chain(s) based on
the protein sequence. While the primary structures of DNA
molecules and proteins are linear and relatively straightfor-
ward, the branching property allows glycans to have
exceedingly a large number of isomeric primary structures
even if only six basic units are concerned [7]. In contrast to
DNA molecules and proteins, the bonding between two
monosaccharide residues can have a variety of configura-
tions and linkages. There are two different stereochemical
configurations of glycosidic bonds—an alpha linkage and a
beta linkage. The only difference between the alpha and
beta linkages is the orientation of the linked carbon atoms.
Furthermore, each carbon in a monosaccharide can partic-
ipate in such bonding. This flexibility and complexity
cannot be addressed by using conventional analytical
approaches in genomics and proteomics.
Glycosylation alters the biochemical properties of a
glycoprotein in a number of ways, including an isoelectric
point [8], conformational stability [9], thermal and pH
stabilities [10, 11], susceptibility to inorganic solvent and
proteolysis [12], and a lectin-binding behavior [13]. In
general, glycosylation increases the thermal stability and
reduces the susceptibility of protein to proteolysis, as
demonstrated by various deglycosylated glycoenzymes
[14]. However, the removal of glycosylation does not
always change the biochemical properties of different
glycoproteins in the same way [14]. Therefore, functional
changes brought about by glycosylation not only depend on
the structure of a glycan, but also on the characteristics of
the protein concerned. It is almost impossible to predict the
functional changes brought by the glycans based solely on
their glycan structures. Moreover, a single glycoprotein
molecule may have several glycosylation sites with various
susceptibilities to glycosylation and may carry different
glycan chains independently, leading to a considerable
number of glycoforms with subtle differences in their
properties. For example, serum haptoglobin (Hp) is a
tetramer composed of two alpha subunits of 9.1 kDa and
two beta subunits of 40 kDa. The carbohydrate content of
Hp is found exclusively as ‘complex’ N-linked glycans on
the beta subunit only [15]. There are four N-linked
glycosylation sites on the beta subunit. The glycans are
either biantennary or triantennary, both terminating with
sialic acid residue(s). Fucose is linked to the core GlcNAc
residue at either alpha-1,6 position or alpha-1,3 position
[16]. In our recent study, we observed a total of 18
glycoforms with slight differences in molecular weight
(ranging from 35–44 kDa) and pI value (ranging from 4.6–
5.8) [17]. Given such complicated relationships between
protein biochemical properties and glycosylations, it is
inevitable in glycoproteomics to isolate and study structures
of glycan motifs. This is especially important in biomarkers
research because glycosylation is usually tissue or disease
specific [18, 19]. These allow identification of glycopro-
teins with tissue-specific glycosylations or tracing back the
origin of disease-related differential glycoproteins.
N-linked and O-linked Glycosylations
There are two major types of glycoprotein glycosylation
concerned and studied extensively in biomarker discovery:
N-linked and O-linked glycosylations. It is because they are
commonly associated with secretory glycoproteins found in
the blood. Glycosylphosphatidylinositol (GPI)-anchored
glycoproteins, on the other hand, are bound to plasma
membrane by two fatty acid chains and less readily detected
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in body fluids. The structural and physiological character-
istics of these two types of glycans are more diverse than
those of GPI-anchored glycoproteins.
N-linked glycan is covalently bonded with the amide
group on asparagine residue of proteins. The asparagine
residue is located in a consensus Asn-X-Ser/Thr sequence in
which X can be any amino acid except proline. In some rare
cases, the serine or threonine residue can be replaced with a
cysteine, giving an Asn-X-Cys glycosylation site, as found in
epidermal growth factor receptor [20], a minor glycosylation
site in human transferrin [21] and CD81 molecules [22]. N-
glycans can be classified into three classes based on the
composition and sequence of oligosaccharides: high man-
nose, complex, and hybrid. The high-mannose N-linked
glycan is composed of mainly polymannosyl residues in all
branches. The complex-type glycans have a characteristic N-
acetyllactosamine Gal(β1–4)GlcNAc in every branches.
While the hybrid-type glycan carries both high-mannose
branches and complex branches. Regardless of class, all N-
linked glycans share the common tri-mannosyl core Manα1–
6(Manα1–3)Manβ1–4GlcNAcβ1–4GlcNAc. Each mannose
residue of the tri-mannosyl core at the nonreducing termini
can be extended in an independent manner by oligomannose
(high-mannose type) or N-acetyllactosamine (complex
type), or linked up with two more branches (antennae).
A single N-glycan can therefore carry up to four branches
(tetraantennary). The branching mannose residue in the
core is susceptible to the addition of bisecting GlcNAc
through β1–3 bond through the action of N-acetylgluco-
saminyltransferase-III, while the asparagines-linked
GlcNAc may be fucosylated through the α1–6 bond through
the action of α1–6-fucosyltransferase [23, 24].
O-linked glycans, on the other hand, have more complex
and less defined structures than N-linked glycans. O-linked
glycan is linked to the hydroxyl side chain group on the
serine or threonine residue in the protein. The two most
contrasting differences between O- and N-linked glycans are
the absence of common tri-mannosyl core and a consensus
amino acid sequence on the glycosylation site. In most of the
O-linked glycoproteins, the glycans are mucin type that
carries the core sugar GalNAc, followed by a Gal, GalNAc,
or GlcNAc residue. Unlike N-linked glycans, O-linked
glycans are less branched and usually carry, at most, two
antennae, branching at the core GalNAc by Gals.
In both types of glycosylations, the main monosaccharide
residues encountered are usually hexoses and theirN-acetylated
derivatives, including GlcNAc and N-acetyllactosamine.
Pentoses are rarely found in human glycosylation system
except xylose in O-linked glycans, and their presences are
usually allergenic [25]. Sialic acid, or N-acetylneuraminic
acid, is another important constituent of glycans. It is a nine-
carbon acidic monosaccharide usually found at the termini of
various glycans and on the plasma membrane of vertebrates
and invertebrates. Sialic acid can link up with the terminal Gal
in α2–3 or α2–6 configuration, depending on the cell-type,
tissue-type, developmental stages, and environmental factors
[26]. α2–8 linkage is also found in the terminal polysialic acid
chain in N-linked and O-linked glycans and in ganglioside
[27, 28]. The presence of sialic acid on plasma membrane
increases the hydrophilicity and negative charges of the cell
and masks the Gal residue in the internal sequence to avoid
binding of it with specific receptors [26]. It is also commonly
expressed in microbial pathogen as a molecular mimicry, as
sialic acid is heavily related with cell surface glycoproteins
and cell–cell recognition system [26, 29].
Historical Development and Clinical Application
of Glycobiomarkers
Glycosylation changes have been identified in various
diseases, ranging from systemic genetic diseases like
CDG syndrome [3] to localized malignancy like ovarian
cancers [4]. There has been a long history in applying
glycobiomarkers for disease diagnosis and prognosis.
Glycans with specific sequence are recognized as
antigens in immune system. Besides the ABO blood group
antigens, one of the famous examples is the Lewis antigen
(Le) present on the plasma membrane of red blood cells.
Lewis antigen belongs to a type of cell adhesion molecules
expressed by leukocytes and some circulating cancer cells.
Lewis antigen is recognized by selectin, a family of lectins
expressed by vascular endothelial cells, and assists the
adhesion of leukocytes and cancer cells to endothelia. Four
types of Le antigen are identified: Lea (Galβ1–3(Fucα1–4)
GlcNAc), Leb (Fucα1–2Galβ1–3(Fucα1–4)GlcNAc), Lex
(Galβ1–4(Fucα1–3)GlcNAc), and Ley (Fucα1–2Galβ1–4
(Fucα1–3)GlcNAc). Lea, Lex, and their sialylated
(Neu5Acα1–3Galβ1–4(Fucα1–3)GlcNAc) and sulphated
(SO43-OGalβ1–4(Fucα1–3)GlcNAc, and Neu5Acα1–
3Galβ1–4(Fucα1–3)(SO46-O)GlcNAc) variants are com-
monly associated with cancer cell adhesions. Previous
studies have shown that inhibition of Lea and Lex antigen
expressions in cancer cells greatly reduce their adhesion to
endothelial cells or selectin-expressing cells in vitro, and
the expression of sialyl Lea and sialyl Lex is associated with
tumor progression and metastasis [30]. Because of the
connection between sialyl Lewis antigen and tumorigenicity,
it is not surprising that the expression of sialyl Lea is a useful
prognostic factor in cancers, for example, for colorectal
carcinomas [31–33]. Helicobacter pylori also expresses Lex
and Ley antigens on its cell surface as part of the
lipopolysaccharide to mimic the cell-surface glycoconjugate
molecules of human gastric endothelial cells [34]. They are
responsible for the adhesion of H. pylori, the infection and
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colonization of which cause chronic gastritis and gastric
cancer.
The glycosylation of immunoglobulin (Ig) is also of
great interest. Immunoglobulin is a well-known circulating
glycoprotein found in serum. It is glycosylated at a
conserved location in heavy chains and at a less conserved
location in light chains. Immunoglobulins are produced and
secreted specifically by Ig-secreting cells and play impor-
tant roles in the immune system. Glycosylation plays a
critical role in modulating the structure and function of Igs.
Alterations in glycan structures of Ig has been observed in a
variety of autoimmune diseases, such as rheumatoid
arthritis and systemic lupus erythematosus [35, 36], as well
as immune-related diseases like IgA nephropathy [37].
Abnormal hypogalactosylated O-glycosylation on the Fc
region in IgA molecules is known to cause mesangial IgA
deposition in kidney in IgA nephropathy, leading to
glomerular damage [37].
The majority of serum glycoproteins are of hepatic
origin. The close relationship between liver and serum
glycoproteins suggests that liver abnormalities associated
with aberrant glycosylations can be reflected by the
changes in serum glycoprotein glycosylation patterns. The
degrees of fucosylation on certain serum glycoproteins,
such as haptoglobin [38], cholinesterase [39], and alpha-1
acid glycoprotein [40], were increased in liver cirrhosis.
Microheterogeneity with concanavalin A affinity of serum
transferrin was observed in patients with alcoholic liver
disease [41]. Altered glycosylation pattern of serum
transferrin can be observed in patients with alcohol abuse.
Carbohydrate deficient transferrin is a well-established
biomarker for detecting alcohol abuse [42–44].
Alternations in glycosylation of glycoproteins and
glycolipids are common in various cancers, and a consid-
erable amount of them play important roles in carcinogen-
esis, such as tumor progression, tumor cell differentiation,
cell–cell interaction, and tumor cell adhesion and metastasis
[45–48]. For examples, downregulation of beta-1,3-N-
acetylglucosaminyl-transferase-T2 expression was observed
in invasive human bladder transitional cell carcinomas
compared with their noninvasive counterparts, suggesting
that downregulation of this glycosylation enzyme may be
involved in cancer progression [45]. In colorectal cancers,
mRNA expressions of various glycosyltransferases are
significantly altered [46]. Elevated mRNA expression of
alpha1–6 fucosyltransferase in human hepatoma tissues was
associated with the production of tumor-specific fucosy-
lated alpha-fetoprotein (AFP) glycoform [47]. The changes
of glycosylation machinery in the cancer cells can be
reflected in the blood circulation by tracing the changes in
the glycosylation of the proteins released by the tumor [48].
The poor specificity of a tumor marker is often because
of the fact that it is also produced by normal cells under
other pathological conditions. As tumor cells have different
glycosylation machinery, it is hypothesized that identifica-
tion of tumor-specific glycoforms should improve the
specificity of a tumor marker. This hypothesis has been
supported by various studies showing that identification of
tumor-specific glycoforms can improve the diagnostic value
of serum AFP. AFP is an N-glycosylated serum glycopro-
tein carrying a biantennary complex type glycan [49] and is
a well-documented upregulated biomarker for hepatocellu-
lar carcinoma (HCC). However, it was also found to be
elevated in chronic liver diseases, reducing its specificity in
diagnosis HCC. By using lectin-affinity electrophoresis, an
elevated level of core alpha1–6-fucosylated AFP glycoform
called AFP-L3 can differentiate between chronic liver
diseases and HCC, demonstrating the application of altered
glycosylation in biomarker discovery [47, 50]. Apart from
AFP-L3, a monosialylated glycoform of AFP termed
msAFP was also found to be able to differentiate between
early stage HCC with nondiagnostic AFP level and liver
cirrhosis patients with similar total serum AFP level [51].
These studies have shown that, although total serum AFP
alone was not sufficient to differentiate HCC and chronic
liver diseases, the qualitative and quantitative information
of the N-glycosylation pattern of serum AFP have signif-
icantly improved the performance of AFP as a HCC-
specific biomarker. Besides AFP, it has been reported that
serum levels of fucosylated glycoforms of alpha-1 anti-
trypsin and transferrin in patients with HCC are signifi-
cantly higher than with liver cirrhosis [52, 53, 54].
Haptoglobin is a serum glycoprotein carrying sialylated
complex type biantennary N-glycan. Changes in the
haptoglobin glycosylation pattern have been studied as
early as 1992 in ovarian cancer [36] and in canine diseases
in the past decade [55, 56]. Serum haptoglobin level was
found to be elevated in serum of HCC patients [17], and the
fucosylated glycoform of haptoglobin with altered sialyla-
tion was found to be associated with tumor progression,
enhancing its value as HCC biomarker [17]. Recently,
aberrantly glycosylated haptoglobin has been shown to be a
potential biomarker for other cancer types, including non-
small cell lung cancer [57], prostate cancer [58], and
pancreatic cancer [59].
Glycomics—An Uprising Approach for Biomarker
Discovery
Glycome refers to a repertoire of glycans in a tissue/cell
type. Glycomics is the study of glycome. Glycomics is
becoming a hot research field in the recent years. There
have been considerable advances in mass spectrometry
(MS) technologies and oligosaccharide analysis technolo-
gies, including techniques in derivatization, fluorescent
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labeling, capillary electrophoresis (CE), and high-performance
liquid chromatography (HPLC), making glycomics study
possible. Recent advances of analytical technologies also
allow more effective differentiation of isomeric and anomeric
glycans, which can visualize the glycome with higher
resolution. Similar to genomics and proteomics studies,
glycomics studies rely on high-throughput screening to
identify a panel of distinguishable glycomic features simulta-
neously. Glycomics study usually involves a large-scale
systemic analysis of glycan pools, which usually contain
several subtypes such as N-linked and O-linked glycans and
glycans from glycolipid. Among these glycan subgroups,
their structural properties, such as sequences and extent of
branching and sialylation, differ from each other significantly
as mentioned above. The analytical approaches for these
subgroups hence are also different.
Moreover, as mentioned in the last section, glycans have
been recognized as a valuable source of biomarkers for
various diseases. Glycomic analysis allows rapid global
comparison of glycome within body fluids or tissues of
interest, which would allow identification and application
of a new type of biomarkers for cancer diagnosis and to
monitor cancer development and treatment. With the
establishment of powerful high-throughput technologies,
the analysis of glycome—a complex mixture with signifi-
cant biological importance—has become a surmountable
task. Unlike genomic or proteomic biomarkers, which
directly or indirectly rely on transcriptional or translational
information, glycomics allows biomarker researches to
focus solely on the posttranslational events within the cells.
It should be pointed out that there are several differences
between glycoproteomics and glycomics. Glycoproteomics
aims to enrich, quantify, separate, and identify low
abundant glycoproteins with specific glycosylation. There-
fore, glycoproteomics focuses on a subset of proteome
characterized by the presence of glycosylation on proteins,
and proteins remain the main subject of study [60]. In
glycoproteomics study, a specific glycoform of a glycopro-
tein, such as monosialylated AFP, will be identified as a
biomarker. Glycomics, on the other hand, focuses on
structures and sequences of glycan motifs, and the
conjugated molecules are not the main concern. The focus
of this review is mainly on the applications of glycomics to
biomarker discovery, while glycoproteomics is not covered.
Human Proteome Organization Human Disease
Glycomics/Proteome Initiative
Human disease glycomics/proteome initiative (HGPI) was
launched by Human Proteome Organization. The major aim
of HGPI is to identify disease-related glycobiomarkers in
biological fluids mainly by undertaking functional glyco-
mics and high-throughput MS approaches. To achieve this,
HGPI has attempted to develop a common data and
analytical standard method of N-glycans for various
diseases. Ultimately, a common database platform will be
developed. Since October 2004, several projects were
carried out by HGPI, including the development of a
standard methodology for glycome analysis of glycans
carried by human transferrin and IgG and the development
of a diagnostic program for CDGs. The result of method
development was noteworthy. It made a comprehensive and
quantitative comparison between the merits and drawbacks
of different analytical approaches [61]. The ongoing CDG
program, on the other hand, aims to complement traditional
methods for classification of the symptom through genetics
and to discover new subtypes of the symptom. This
anticipation by the global proteomics community clearly
illustrates the worldwide awareness of the importance of
glycomics in biomarker research.
In August 2007, the National Cancer Institute (NCI),
which is part of the National Institutes of Health in the
USA, had funded a new US$ 15.5-million 5-year initiative
consisting of seven projects on glycomic biomarker research
with aims to discover novel cancer biomarkers and to
improve preexisting ones. All seven projects (Table 1) are
focused on either serum glycomic biomarkers or anti-glycan
autoantibodies. Majority of these projects focused mainly on
cancers with poor prognosis, including pancreas cancer and
breast cancer. This campaign has highlighted the importance
of glycomics in biomarker discovery and the advent of
glycomics in this postgenome era.
Recent Applications of Glycomics to Biomarker
Discovery
Owing to technological limitations to elucidate the complex
information of various glycans including sequences, struc-
tures, and quantities, early studies of glycosylation
remained at the level of separation of protein glycoforms
based on isoelectric focusing or lectin-affinity electropho-
resis and subsequent identification by immunoblotting [42–
44, 50]. Recently, the development and maturation of more
sophisticated analysis platforms like MS and bioinformatics
allow more in-depth studies and high-throughput analyses
on glycosylations. These have accelerated the utilization of
glycosylation as a new source of biomarkers, as differential
glycans can now be assessed more accurately and precisely
at a larger scale. Aberrant glycosylation has gained much
attention in biomarker researches, especially in liver
diseases and cancers.
Except for the use of lectin microarrays, in most cases, it
is inevitable in glycomic study to deglycosylate the
glycoconjugate of interest (glycoprotein, glycolipid, or
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lipopolysaccharide) and to retrieve the free glycan mole-
cules for downstream analysis. The whole workflow can be
roughly divided into three parts: deglycosylation, purifica-
tion, and quantitative analysis (Fig. 1).
The number of glycomic researches and glycobiomarker
studies has been gradually rising in the beginning of this
century. A brief summary of all articles published in
relation with glycomics was given in this review to provide
an overview of this growing field. In 2004, the global
pattern of desialylated N-linked glycans from whole serum
proteins was successfully profiled by using a DNA
sequencer as a CE instrument and subsequently used to
detect liver cirrhosis [18, 62]. Four glycomic features were
found to be significantly different in liver cirrhosis patients
compared with control, and all upregulated features were
shown to be fucosylated and carry a bisecting GlcNAc. Log
ratio of two of these features gave a receiver operating
characteristic (ROC) curve area of 0.87 in classifying mild
fibrosis and compensated liver cirrhosis. In 2007, the same
approach was applied to identify N-glycomic changes in
HCC patients with hepatitis B virus-induced liver cirrhosis
[63]. Two fucosylated glycomic features, one of them
Table 1 The seven biomarker discovery projects funded by NCI by targeting glycans (information source: http://www.nih.gov/news/pr/aug2007/
nci-21.htm)
Project title Objectives of project
Discovery and clinical validation of cancer
biomarkers using printed glycan array
Determine the diagnostic or prognostic anti-glycan autoantibody signatures
in patients. For breast cancer, determine how many years before diagnosis that
progression to cancer can be predicted
Immunogenic sugar moieties of prostate cancers Identify anti-glycan autoantibody signatures in prostate cancer patients
Early cancer detection and prognosis through
glycomics
Identify biomarkers from glycans released from serum glycoproteins and
develop high-throughput platforms to measure biomarkers suitable for the clinic
Glycan markers for the early detection of
breast cancer
Identify breast cancer biomarkers based on aberrant glycan modifications on
defined amino acid residues of serum glycoproteins
Tumor glycomics laboratory for discovery of
pancreatic cancer markers
Identify glycoprotein and glycolipid biomarkers for pancreatic cancer in pancreatic
ductal fluid that can also be found in serum. Develop assays for promising biomarkers
Autoantibodies against glycopeptide epitopes as
serum biomarkers of cancer
Determine autoantibody signatures to mucin glycopeptides in pancreatic and breast
cancer patients
Neu5Gc and anti-Neu5Gc antibodies for detection
of cancer and cancer risk
Expand on research showing that cancer patients express cell surface glycans
containing the sialic acid N-glycolylneuraminic Acid (Neu5Gc) and produce
autoantibodies to these structures
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carrying bisecting GlcNAc, were found to be associated
with HCC. The log ratio of these two features gave an ROC
curve area of 0.81 in diagnosing HCC, which is comparable
with that of using AFP.
Apart from CE, a matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) MS approach has
been successfully applied to obtain the quantitative profiles
of N-linked glycans from the whole serum proteins without
the need of desialylation and has been applied to identify
potential N-glycomic biomarkers for liver fibrosis and liver
cirrhosis [19]. N-glycans were released from whole serum
proteins by PNGase F digestion and were purified by
hydrophilic chromatography. Finally, they were profiled by
linear MALDI-TOF MS. A total of 17 differential N-
glycans were identified that correlated with degree of liver
fibrosis. Four of these N-glycans were selected by using
linear regression for the construction of diagnostic model.
By using linear regression, a diagnostic model was
constructed from the potential diagnostic N-glycans. It gave
an ROC curve area of 0.91 for detecting liver fibrosis and
0.911 for detecting liver cirrhosis in the pilot study. In a
similar study [64], the N-glycans released were purified by
HPLC on graphitized carbon columns, and subsequently
subjected to either desialylation or methyl-esterification
before MALDI-TOF MS analysis. MALDI-TOF MS was
also used in conjunction with a novel type of sepharose
beads to profile total serum N-glycan [65]. The sepharose
bead was functionalized with a hydrazide polymer to
facilitate the immobilization of free glycans through
hydrazone bond, which allowed on-beads methyl-esterifi-
cation of sialic acid. The technology was applied to study
three types of diseases: CDGs, HCC, and prostate cancer. It
was able to identify serum glycomic features that could
differentiate type 1 and type 2 CDG from healthy normal
controls and HCC from health normal controls. The method
also allowed analysis of total cellular glycan profiles of
human prostate cancer cells and normal human prostate
epithelial cells.
Apart from N-glycans, total serum O-glycomic pattern
was also profiled by MALDI-Fourier transform ion cyclo-
tron resonance (FTICR) MS and applied to discover
biomarkers for ovarian cancer [66]. A unique serum O-
glycomic profile containing 16 cancer-specific signatures
was obtained from patients with ovarian cancer. Infrared
multiphoton dissociation was applied to glycan sequencing.
The diagnostic features identified in the spectra were
confirmed to be oligosaccharides but not peptides. Later,
the same approach was applied to search for potential
biomarkers for breast cancer in mouse and human [67].
Principle component analysis of the O-glycomic profiles
had successfully distinguished breast cancer samples from
normal samples. A summary of the above studies was given
in Table 2.
Technologies for Quantitative Profiling of Tissue
Glycome
Quantitative profiling is essential for the identification of
differential features in biomarker discovery. Among the
technologies mentioned above, HPLC and CE are well
known for their quantitative performance. The detection
methods of glycans in these systems are based on the
measurement of fluorescent signal of the derivatized
glycans. As long as there is neither detector saturation nor
substrate bias during derivatization, the signal intensity
should be proportional to amount of analytes. CE has been
demonstrated to be quantitative in analyzing native and
derivatized glycosaminoglycans [68].
The quantitative aspect of glycan analysis in MALDI-
TOF MS is affected by various parameters including
analyte derivatization, types of laser, spotting protocol,
choice of matrix, and acquisition protocol of spectrum.
Structure of glycans, on the other hand, does not signifi-
cantly affect the quantitative performance of MALDI-TOF
MS [69], although it has been suspected that an extra
antenna may promote postsource decay [61]. To obtain a
quantitative profile of glycome by MALDI-TOF MS,
methyl-esterification of the sialic acid residues is usually
required to prevent the loss of sialic acid during MS
analysis. However, our recent study has shown that
sialylated glycan could be already quantified in the
presence of 10 mM NaCl, but without the need of
methyl-esterification [19]. In proteomic study, it had been
shown that the reproducibility of MALDI-TOF mass
spectra was greatly affected by the spotting methods, such
as direct mixing, overlaying, and sandwiching [70]. Simi-
larly, such parameter should also dictate the quantitative
performance of MALDI-TOF MS in glycan analysis.
The reproducibility of the signal intensity of a glycan
depends on (1) the quality of the glycan-matrix co-crystal on
the sample spot and (2) the laser scanning protocol. The
variation of signal intensities can be minimized by obtaining
more mass spectra over different areas on the sample spot and
averaging the resulting spectra. From a multi-institutional
study, the intra-assay and inter-assay coefficients of variation
percentages of glycans released from human IgG were below
10% and 4.2% for major species and 34% and 13% for minor
species [61]. In a separate study, the intra-assay and inter-
assay coefficients of variation percentages of three different
standard glycans were below 9% and 18%, respectively [19].
This suggests that the quantitative performance of MALDI-
TOF MS is comparable to chromatography. However, the
multi-institutional study clearly illustrated that there were
considerable variations between different centers [61]. More
efforts have to be made to standardize the protocols and
instrumentation to obtain comparable mass spectra from
different research centers. Themajor shortcoming ofMALDI-
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TOF MS is its incapability to provide concrete structure
information of the glycan detected, although it is possible to
predict structures of glycans based on molecular weights
obtained from MS [19]. In the future, a similar approach
could be carried out with a MALDI-TOF/TOF MS system to
allow direct structure analysis by tandem MS. Besides a
combined use of MALDI and TOF MS, MALDI has been
combined with FTICR MS to obtain quantitative glycomic
profiles [66, 67]. However, the reproducibility of the
MALDI-FTICR MS in quantitative glycomic profiles has
not been systematically evaluated.
Comparable to gene expression microarray and antibody
microarray, lectin microarray was a newly developed
technology for glycomics and glycoproteomics studies.
Lectins are highly specific carbohydrate-binding biomole-
cules that recognizes glycans by their structural informa-
tion. Different types of lectins recognize different
oligosaccharide structures, terminal residue, and linkage
[71]. For example, galectins are specific toward Gal residue
[72]; siglecs are a group of I-type lectins, which mediate
glycan recognition via Ig-like domains [73], and selectins
are expressed by leukocytes and endothelial cells to
recognize sialyl Lewis antigens [74]. Lectins have been
widely used to study and isolate glycoproteins. Lens
culinaris agglutinin lectin, which binds specific to alpha-
1,6 fucosylation at proximal core GlcNAc, has been applied
to isolate fucosylated AFP glycoforms associated with
HCC [75]. Ricinus communis agglutinin lectin, which binds
β-Gal, was applied on monitoring the desialylation of
glycoproteins in murine B16 melanoma cells [76] and on
investigating the degree of galactosylation of glycoproteins
in human astrocytoma [77]. Sambucus nigra agglutinin
lectin, which recognizes alpha 2,6-linked sialic acid, was
used to measure the degree of alpha 2,6-sialylation of
glycoproteins in human colon cancer [78]. Binding of Helix
pomatia agglutinin lectin, which recognizes GalNAc, to
human cutaneous malignant melanoma was found to be
associated with metastasis formation [79]. Peanut lectin,
which binds Galβ1−3GalNAc, was used to measure levels
of mucin-type O-glycan in the human benign and malignant
colorectal tissues [80].
In the lectin microarray technology, a panel of lectins is
immobilized onto solid support in a microarray format. This
allows simultaneous detection of glycans based on their
interaction with different lectins. Lectin microarray was
first developed in 2004 [81]. It has been shown that a lectin
microarray spotted with nine lectins was already capable of
giving distinct glycoprofiles for different glycoproteins
[82]. In the experiment, lectin microarray was exposed to
fluorescence-tagged glycoproteins, followed by washing
and scanning. The experiment outcome was a pattern of
lectins that interact with the glycans of glycoproteins. When
a purified glycan or glycoprotein is analyzed with the lectin
microarray, the structure of the glycan can then be
interpreted based on the interaction pattern. Moreover,
lectin microarrays can be used to study glycan–lectin
interaction in a high-throughput manner [83].
Because the affinity of lectins to glycans was relatively low
(Kd=10
–4 to 10–7M) compared with antibody–antigen inter-
action (Kd=10
–8 to 10–12M), various techniques have been
developed to avoid loss of analytes during washing and to
probe such weak interactions such as the evanescent-field
fluorescence detection [83] and the ratiometric approach [84].
An evanescent field is a weak electric field that only
propagates wavelength distance from the sensor surface. It
allows real-time detection during the interaction event
between lectins and glycans, thus omitting the need of
washing. While the ratiometric approach utilizes dual fluores-
cence colors similar to DNA microarrays for different
samples, allowing ratiometric comparison between glycomes.
This approach was also shown to be able to analyze complex
mixture including the total glycome of whole-cell lysates [84].
The quantitative performance of lectin microarray has been
well evaluated [82]. The signal intensity was linear for
glycoproteins in the range of 50 to 300 μg/ml. Coefficient
of variation of signal intensities was within 10% to 20% [83].
Although lectin microarray also detects fluorescence
signal associated with the glycans, there are several ways
that are different from the approaches based on HPLC or
CE. Firstly, in the lectin microarray technology, fluorescent
tags could be attached to protein portions of the glyco-
conjugates, instead of the glycan molecules. Hence, the
glycoproteins or glycoconjugates can be applied directly to
the array without deglycosylation and desialylation. This
simplifies the experimental process and allows more
labeling options and downstream analysis as well as
simultaneous analysis of O-linked, N-linked, and glycolipid
glycans [82]. Secondly, lectin microarray belongs to the
type of competition assays. Different glycoproteins having
the same glycan structures will compete for the same group
of lectins. It is not uncommon that different glycoproteins
are labeled with a different number of fluorescent tags,
leading to variations in the signal intensities between
experiments. Furthermore, a single lectin molecule can
bind to glycan molecules with different structures, but at
different affinities. When a mixture of glycoproteins or
glycoconjugates is subjected to a lectin microarray analysis,
a highly complex pattern of competition and interaction
among glycans and lectins will result.
Future Prospective
As glycosylation changes have been associated with a wide
range of diseases, it can be foreseen that glycomics holds
the promise for biomarker discovery. Currently, HPLC and
76 Clin Proteom (2008) 4:67–79
MS are the most popular analytical platforms for glyco-
biomarker researches. Although elucidation of glycan
structures is not necessary for biomarker studies, it is still
highly recommended to distinguish isomeric and anomeric
compounds and to validate the biological significance of
the result. In the past 10 years, the detection sensitivities of
various MS technologies have been greatly improved,
while new tandem MS technologies have been invented
to elucidate the glycan structures. MS-based approaches
will be very important in glycomics in the near future
and provide a practical and reliable solution for high-
throughput quantitative profiling of tissue glycome.
Multiple reaction monitoring (MRM) has been recently
used to quantity a panel of targeted serum proteins [85].
Its application to quantitative glycan profiling is still
under exploration. When a panel of disease-associated
glycans is discovered, a clinically practical assay based
on MRM can be developed. Because of the isomeric and
anomeric natures of oligosaccharides, the separation and
characterization of these isomers remain a challenging
task, especially if high-throughput screening is required.
Lectin microarray may provide a practical solution to
this, but it is still in its infant stage. Above all, there is no
doubt that glycomics is gaining momentum in biomarker
research.
References
1. Werner RG, Kopp K, Schlueter M. Glycosylation of therapeutic
proteins in different production systems. Acta Paediatr Suppl.
2007;96:17–22.
2. Devasahayam M. Factors affecting the expression of recombinant
glycoproteins. Indian J Med Res. 2007;126:22–7.
3. Eklund EA, Freeze HH. The congenital disorders of glycosylation:
a multifaceted group of syndromes. NeuroRx 2006;3:254–63.
4. Leiserowitz GS, Lebrilla C, Miyamoto S, et al. Glycomics
analysis of serum: a potential new biomarker for ovarian cancer?
Int J Gynecol Cancer 2007;18:470–5.
5. He YD. Genomic approach to biomarker identification and its
recent applications. Cancer Biomark. 2006;2:103–33.
6. Cai Z, Chiu JF, He QY. Application of proteomics in the study of
tumor metastasis. Genomics Proteomics Bioinformatics. 2004;
2:152–66.
7. Laine RA. Invited commentary: a calculation of all possible
oligosaccharide isomers both branched and linear yields 1.05×1012
structures for a reducing hexasaccharide: the Isomer Barrier to
development of single-method saccharide sequencing or synthesis
systems. Glycobiology. 1994;4:759–67.
8. Belalcazar V, Gutiérrez Gallego R, Llop E, Segura J, Pascual JA.
Assessing the instability of the isoelectric focusing patterns of
erythropoietin in urine. Electrophoresis. 2006;27:4387–95.
9. Barbaric S, Mrsa V, Ries B, Mildner P. Role of the carbohydrate
part of yeast acid phosphatase. Arch Biochem Biophys.
1984;234:567–75.
10. Takegawa K, Inami M, Yamamoto K, et al. Elucidation of the
role of sugar chains in glucoamylase using endo-beta-N-
acetylglucosaminidase from Flavobacterium sp. Biochim Biophys
Acta. 1988;955:187–93.
11. Tsuji Y, Yamamoto K, Tochikura T. Formation of deglycosylated
alpha-L-fucosidase by endo-beta-N-acetylglucosaminidase in
Fusarium oxysporum. Appl Environ Microbiol. 1990;56:928–33.
12. Chu FK, Maley F. Stabilization of the structure and activity of
yeast carbosypeptidase Y by its high-mannose oligosaccharide
chains. Arch Biochem Biophys. 1982;214:134–9.
13. Sarter K, Mierke C, Beer A, et al. Sweet clearance: involvement
of cell surface glycans in the recognition of apoptotic cells.
Autoimmunity. 2007;40:345–8.
14. Yamamoto K. Microbial endoglycosidases for analyses of oligo-
saccharide chains in glycoproteins. J Biochem. 1994;116:229–35.
15. Dobryszycka W. Haptoglobin: retrospectives and perspectives. In:
Mackiewicz A, Kushner I, Baumann H, editors. Acute phase
proteins: molecular biology, biochemistry, and clinical applica-
tions. Boca Raton: CRC Press; 1993. p. 185–206.
16. Nilsson B, Lowe M, Osada J, Ashwell G, Zopf D. The
carbohydrate structure of human haptoglobin 1–1. In: Yamakawa
T, Osawa T, Handa S, editors. Glycoconjugates. Tokyo: Japan
Scientific Societies Press; 1981. pp. 275–6.
17. Ang IL, Poon TC, Lai PB, et al. Study of serum haptoglobin and
its glycoforms in the diagnosis of hepatocellular carcinoma: a
glycoproteomic approach. J Proteome Res. 2006;5:2691–700.
18. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W,
Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis
using DNA sequencer-based total serum protein glycomics. Nat
Med. 2004;10:429–34.
19. Kam RK, Poon TC, Chan HL, Wong N, Hui AY, Sung JJ. High-
throughput quantitative profiling of serum N-glycome by MALDI-
TOF mass spectrometry and N-glycomic fingerprint of liver
fibrosis. Clin Chem. 2007;53:1254–63.
20. Sato C, Kim JH, Abe Y, Saito K, Yokoyama S, Kohda D.
Characterization of the N-oligosaccharides attached to the atypical
Asn-X-Cys sequence of recombinant human epidermal growth
factor receptor. J Biochem. 2000;127:65–72.
21. Satomi Y, Shimonishi Y, Takao T. N-glycosylation at Asn-491 in
the Asn-Xaa-Cys motif of human transferrin. FEBS Letter.
2004;576:51–6.
22. Sasaki M, Yamauchi K, Nakanishi T, Kamogawa Y, Hayashi N. In
vitro binding of hepatitis C virus to CD81-positive and -negative
human cell lines. J Gastroenterol Hepatol. 2003;18:74–9.
23. Stanley P. Biological consequences of overexpressing or eliminating
N-acetylglucosaminyltransferase-TIII in the mouse. Biochim Biophys
Acta 2002;19:363–8. 1573.
24. Miyoshi E, Noda K, Yamaguchi Y, et al. The alpha1–6-
fucosyltransferase gene and its biological significance. Biochim
Biophys Acta. 1999;1473:9–20.
25. Fötisch K, Vieths S. N- and O-linked oligosaccharides of
allergenic glycoproteins. Glycoconj J. 2001;18:373–90.
26. Varki A. Glycan-based interactions involving vertebrate sialic-
acid-recognizing proteins. Nature. 2007;446:1023–9.
27. Harduin-Lepers A, Recchi MA, Delannoy P. 1994, the year of
sialyltransferases. Glycobiology. 1995;5:741–58.
28. Harduin-Lepers A, Krzewinski-Recchi MA, Hebbar M, et al.
Sialyltransferases and breast cancer. Recent Res Dev Cancer
2001;3:111–26.
29. Vimr ER, Kalivoda KA, Deszo EL, Steenbergen SM. Diversity of
microbial sialic acid metabolism. Microbiol Mol Biol Rev.
2004;65:132–53.
30. Ugorski M, Laskowska A. Sialyl Lewis: a tumor-associated
carbohydrate antigen involved in adhesion and metastatic poten-
tial of cancer cells. Acta Biochim Pol. 2002;49:303–11.
31. Shimono R, Mori M, Akazawa K, Adachi Y, Sugimachi K.
Immunohistochemical expression of carbohydrate antigen 19–9 in
colorectal carcinoma. Am J Gastroenterol. 1994;89:101–5.
Clin Proteom (2008) 4:67–79 77
32. Nakayama T, Watanabe M, Katsumata T, Teramoto T, Kitajima M.
Expression of sialyl Lewisa as a new prognostic factor for patients
with advanced colorectal carcinoma. Cancer. 1995;75:2051–6.
33. Yamada N, Chung YS, Arimoto Y, et al. Increased sialyl Lewis A
expression and fucosyltransferase activity with acquisition of a
high metastatic capacity in a colon cancer cell line. Br J Cancer.
1997;76:582–7.
34. Moran AP, Prendergast MM. Molecular mimicry in Campylobacter
jejuni and Helicobacter pylori lipopolysaccharides: contribution of
gastrointestinal infections to autoimmunity. J Autoimmun. 2001;
16:214–56.
35. Wuhrer M. Glycosylation profiling in clinical proteomics: heading
for glycan biomarkers. Expert Rev Proteomics. 2007;4:135–6.
36. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The
impact of glycosylation on the biological function and structure of
human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.
37. Giannakakis K, Feriozzi S, Perez M, Faraggiana T, Muda AO.
Aberrantly glycosylated IgA1 in glomerular immune deposits of
IgA nephropathy. J Am Soc Nephrol 2007;18:3139–46.
38. Mann AC, Record CO, Self CH, Turner GA. Monosaccharide
composition of haptoglobin in liver diseases and alcohol abuse:
large changes in glycosylation associated with alcoholic liver
disease. Clin Chim Acta 1994;227:69–78.
39. Kondo M, Hada T, Fukui K, Iwasaki A, Higashino K, Yasukawa
K. Enzyme-linked immunosorbent assay (ELISA) for Aleuria
aurantia lectin-reactive serum cholinesterase to differentiate liver
cirrhosis and chronic hepatitis. Clin Chim Acta 1995;243:1–9.
40. Ryden I, Pahlsson P, Lindgren S. Diagnostic accuracy of alpha(1)-
acid glycoprotein fucosylation for liver cirrhosis in patients
undergoing hepatic biopsy. Clin Chem 2002;48:2195–201.
41. Inoue T, Yamauchi M, Toda G, Ohkawa K. Microheterogeneity
with concanavalin A affinity of serum transferrin in patients with
alcoholic liver disease. Alcoholism: Clinical & Experimental
Research 1996;20:363A–5A.
42. Xin Y, Lasker MJ, Rosman AS, Lieber CS. Isoelectric focusing/
Western blotting: a novel and practical method for quantitation of
carbohydrate-deficient transferrin in alcoholics. Alcohol Clin Exp
Res. 1991;15:814–21.
43. Stibler H. Carbohydrate-deficient transferrin in serum: a new
marker of potentially harmful alcohol consumption reviewed. Clin
Chem. 1991;37:2029–37.
44. Bean P, Peter JB. A new approach to quantitate carbohydrate-
deficient transferrin isoforms in alcohol abusers: partial iron
saturation in isoelectric focusing/immunoblotting and laser densi-
tometry. Alcohol Clin Exp Res. 1993;17:1163–70.
45. Gromova I, Gromov P, Celis JE. A novel member of the
glycosyltransferase family, beta 3 Gn-T2, highly downregulated
in invasive human bladder transitional cell carcinomas. Mol
Carcinog. 2001;32:61–72.
46. Petretti T, Kemmner W, Schulze B, Schlag PM. Altered mRNA
expression of glycosyltransferases in human colorectal carcinomas
and liver metastases. Gut. 2000;46:359–66.
47. Noda K, Miyoshi E, Uozumi N, et al. Gene expression of α1–6
fucosyltransferase in human hepatoma tissues: a possible impli-
cation for increased fucosylation of α-fetoprotein. Hepatol.
1998;28:944–52.
48. Durand G, Seta N. Protein glycosylation and diseases: blood and
urinary oligosaccharides as markers for diagnosis and therapeutic
monitoring. Clin Chem. 2000;46:795–805.
49. Johnson PJ, Poon TCW, Hjelm NM, et al. Glycan composition of
serum alpha-fetoprotein in patients with hepatocellular carcinoma
and non-seminomatous germ cell tumour. Br J Cancer.
1999;81:1188–95.
50. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocel-
lular carcinoma based on altered profiles of alpha-fetoprotein.
New Engl J Med. 1993;328:1802–6.
51. Poon TCW, Mok TSK, Chan ATC, et al. Quantification and utility
of monosialylated α-fetoprotein in the diagnosis of hepatocellular
carcinoma with nondiagnostic serum total α-fetoprotein. Clin
Chem. 2002;48:1021–7.
52. Yamashita K, Koide N, Endo T, Iwaki Y, Kobata A. Altered
glycosylation of serum transferrin of patients with hepatocellular
carcinoma. J Biol Chem. 1989;264:2415–23.
53. Matsumoto K, Maeda Y, Kato S, Yuki H. Alteration of
asparagine-linked glycosylation in serum transferrin of patients
with hepatocellular carcinoma. Clinica Chimica Acta. 1994;
224:1–8.
54. Naitoh A, Aoyagi Y, Asakura H. Highly enhanced fucosylation of
serum glycoproteins in patients with hepatocellular carcinoma. J
Gastroenterol Hepatol. 1999;14:436–45.
55. Andersson M, Stenström M, Vatne M, Sevelius E, Jönsson L.
Disease-related variations of the glycosylation of haptoglobin in
the dog. J Comp Pathol. 1998;119:227–38.
56. Andersson M, Sevelius E. Abnormal microheterogeneity of
haptoglobin in serum from dogs with various diseases. Vet Rec.
2001;148:14–7.
57. Hoagland LF 4th, Campa MJ, Gottlin EB, Herndon JE 2nd, Patz
EF Jr. Haptoglobin and posttranslational glycan-modified deriva-
tives as serum biomarkers for the diagnosis of nonsmall cell lung
cancer. Cancer. 2007;110:2260–8.
58. Fujimura T, Shinohara Y, Tissot B, et al. Glycosylation status
of haptoglobin in sera of patients with prostate cancer vs.
benign prostate disease or normal subjects. Int J Cancer 2008;
122:39–49.
59. Okuyama N, Ide Y, Nakano M. Fucosylated haptoglobin is a
novel marker for pancreatic cancer: a detailed analysis of the
oligosaccharide structure and a possible mechanism for fucosylation.
Int J Cancer. 2006;118:2803–8.
60. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and
quantification of N-linked glycoproteins using hydrazide chemis-
try, stable isotope labeling and mass spectrometry. Nat Biotechnol.
2003;21:660–6.
61. Wada Y, Azadi P, Costello CE, et al. Comparison of the methods
for profiling glycoprotein glycans-HUPO human disease glycomics/
proteome initiative multi-institutional study. Glycobiology. 2007;
17:411–22.
62. Desmyter L, Fan YD, Praet M, et al. Rating of CCl4-induced rat
liver fibrosis by blood serum glycomics. J Gastroenterol Hepatol.
2007;22:1148–54.
63. Liu XE, Desmyter L, Gao CF, et al. N-glycomic changes in
hepatocellular carcinoma patients with liver cirrhosis induced by
hepatitis B virus. Hepatology. 2007;46:1426–35.
64. Morelle W, Flahaut C, Michalski JC, Louvet A, Mathurin P, Klein
A. Mass spectrometric approach for screening modifications of
total serum N-glycome in human diseases: application to cirrhosis.
Glycobiology. 2006;16:281–93.
65. Miura Y, Hato M, Shinohara Y, et al. BlotGlycoABCä: An
integrated glycoblotting technique for rapid and large-scale
clinical glycomics. Mol Cell Proteomics. 2008;7:370–7.
66. An HJ, Miyamoto S, Lancaster KS, et al. Profiling of glycans in
serum for the discovery of potential biomarkers for ovarian
cancer. J Proteome Res. 2006;5:1626–35.
67. Kirmiz C, Li B, An HJ, et al. A serum glycomics approach to
breast cancer biomarkers. Mol Cell Proteomics. 2007;6:43–55.
68. Mao W, Thanawiroon C, Linhardt RJ. Capillary electrophoresis
for the analysis of glycosaminoglycans and glycosaminoglycan-
derived oligosaccharides. Biomed Chromatogr. 2002;16:77–94.
69. Harvey DJ. Quantitative aspects of the matrix-assisted laser
desorption mass spectrometry of complex oligosaccharides. Rapid
Commun Mass Spectrom. 1993;7:614–9.
70. Pang RTK, Johnson PJ, Chan CML, et al. Technical evaluation of
MALDI-TOF mass spectrometry for quantitative proteomic
78 Clin Proteom (2008) 4:67–79
profiling: matrix formulation and application. Clinical Proteomics
Journal. 2004;1:259–70.
71. Sharon N, Lis H. History of lectins: from hemagglutinins to
biological recognition molecules. Glycobiology 2004;14:53R–62R.
72. Barondes SH, Castronovo V, Cooper DMW, et al. Galectins: a family
of animal β-galactoside-binding lectins. Cell. 1994;76:597–8.
73. Crocker PR. Siglecs: sialic-acid-binding immunoglobulin-like
lectins in cell–cell interactions and signalling. Curr Opin Struct
Biol. 2002;12:609–15.
74. Romano SJ. Selectin antagonists: therapeutic potential in asthma
and COPD. Treat Respir Med. 2005;4:85–94.
75. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor
marker for hepatocellular carcinoma. Clin Chim Acta. 2001;
313:15–9.
76. Kato T, Wang Y, Yamaguchi K, et al. Overexpression of
lysosomal-type sialidase leads to suppression of metastasis
associated with reversion of malignant phenotype in murine B16
melanoma cells. Int J Cancer. 2001;92:797–804.
77. Xu S, Zhu X, Zhang S, et al. Over-expression of beta-1,4-
galactosyltransferase I, II, and V in human astrocytoma. J Cancer
Res Clin Oncol. 2001;127:502–6.
78. Dall'Olio F, Chiricolo M, Ceccarelli C, Minni F, Marrano D,
Santini D. Beta-galactoside alpha2,6 sialyltransferase in human
colon cancer: contribution of multiple transcripts to regulation of
enzyme activity and reactivity with Sambucus nigra agglutinin.
Int J Cancer. 2000;88:58–65.
79. Thies A, Moll I, Berger J, Schumacher U. Lectin binding to
cutaneous malignant melanoma: HPA is associated with metastasis
formation. Br J Cancer. 2001;84:819–23.
80. Lin M, Hanai J, Gui L. Peanut lectin-binding sites and mucins in
benign and malignant colorectal tissues associated with schisto-
matosis. Histol Histopathol. 1998;13:961–6.
81. Hirabayashi J. Lectin-based structural glycomics: glycoproteomics
and glycan profiling. Glycoconj J. 2004;21:35–40.
82. Pilobello KT, Krishnamoorthy L, Slawek D, Mahal LK. Devel-
opment of a lectin microarray for the rapid analysis of protein
glycopatterns. Chembiochem. 2005;6:985–9.
83. Kuno A, Uchiyama N, Koseki-Kuno S, et al. Evanescent-field
fluorescence-assisted lectin microarray: a new strategy for glycan
profiling. Nat Methods. 2005;2:851–6.
84. Pilobello KT, Slawek DE, Mahal LK. A ratiometric lectin
microarray approach to analysis of the dynamic mammalian
glycome. Proc Natl Acad Sci U S A. 2007;104:11534–9.
85. Anderson L, Hunter CL. Quantitative mass spectrometric multiple
reaction monitoring assays for major plasma proteins. Mol Cell
Proteomics. 2006;5:573–88.
Clin Proteom (2008) 4:67–79 79
